Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Eunhye Jang"'
Autor:
Myongjae Lee, Eunhye Jang, Jungwoo Lee, SungKu Choi, Won Sik Lee, Nam Seok Baek, Sungsook Lee, Young-Whan Park, Jong-Hwa Lee, Suk-Jae Chung
Publikováno v:
Journal of Analytical Science and Technology, Vol 14, Iss 1, Pp 1-13 (2023)
Abstract Venadaparib (VEN), a next-generation inhibitor of poly (ADP-ribose) polymerases, is under development for oral use in patients having cancers with deoxyribonucleic acid repair defects. The objective of this study was to develop and validate
Externí odkaz:
https://doaj.org/article/fd12115b3a8540f3bb8220e9adb6a776
Publikováno v:
Materials, Vol 12, Iss 10, p 1613 (2019)
The aim of this study was to evaluate the bone regeneration effect of recombinant human bone morphogenetic protein-2 (rhBMP-2) on a subperiosteal bone graft in a rat model. A subperiosteal space was made on the rat calvarium, and anorganic bovine bon
Externí odkaz:
https://doaj.org/article/45a04311df6341c7a2e09a07e948f191
Autor:
Myongjae Lee, In-Gyu Je, Jeong Eun Kim, Yeongran Yoo, Jong-Ha Lim, Eunhye Jang, Yoonsuk Lee, Dong Keun Song, An-Na Moon, Jeong-Ah Kim, Jinah Jeong, Joon-Tae Park, Jung Woo Lee, Ji-Hoon Yang, Chang-Hee Hong, Sun-Young Park, Young-Whan Park, Nam Seok Baek, Sungsook Lee, Kyoung Soo Ha, SungKu Choi, Won Sik Lee
Publikováno v:
Molecular Cancer Therapeutics. 22:333-342
PARP inhibitors have been approved by the FDA for use in the treatment of patients with ovarian, breast, pancreatic, and prostate cancers. PARP inhibitors show diverse suppressive effects on PARP family members and PARP-DNA trapping potency. These pr
Autor:
Eunhye Jang
Publikováno v:
Korean Journal of Poultry Science. 49:53-60
Autor:
Won Sik Lee, SungKu Choi, Kyoung Soo Ha, Sungsook Lee, Nam Seok Baek, Young-Whan Park, Sun-Young Park, Chang-Hee Hong, Ji-Hoon Yang, Jung Woo Lee, Joon-Tae Park, Jinah Jeong, Jeong-Ah Kim, An-Na Moon, Dong Keun Song, Yoonsuk Lee, Eunhye Jang, Jong-Ha Lim, Yeongran Yoo, Jeong Eun Kim, In-Gyu Je, Myongjae Lee
Supplementary Table 1, Supplementary Table 2, Supplementary Figure 1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::658217c63256ede354d5c219e97c7ada
https://doi.org/10.1158/1535-7163.22523860.v1
https://doi.org/10.1158/1535-7163.22523860.v1
Autor:
Fukuda, Masahiro, Eunhye Jang
Publikováno v:
KOREA NEOLITHIC RESEARCH SOCIETY. 40:63-94
Autor:
Haengjin Song, Chorong Shin, Hyun-Jung Kwak, Jongmin Yoon, Hyo-Jung Song, Eunhye Jang, Kyungmi An, In-Gyu Je, Don-Gil Lee, Jung Ho Kim, Seolhee Lee, Dahae Hong, Jisu Kim, Chang-Hee Hong, Yearin Jun
Publikováno v:
Diabetes. 70
G-protein-coupled receptor 40 (GPR40/FFA1/FFAR1), a clinically validated anti-diabetes target, enhances insulin secretion in type 2 diabetes. It is known that the effect of glucose-stimulated insulin secretion (GSIS) in pancreatic β cells is mediate
Autor:
A-Rang Im, Yearin Jun, Jae Eui Shin, Yeongran Yoo, Sohn Te-Ik, Kyungmi An, Chang Min Whan, Jung Ho Kim, Jung-Eun Park, Woojin Jeon, Dahae Hong, Chang-Hee Hong, Eunhye Jang, In-Gyu Je
Publikováno v:
Diabetes. 70
GLP-1R agonists comprise a growing class of agents that deliver unprecedented efficacy in the treatment of diabetes. We discovered promising compounds for the development of a novel small molecule GLP-1R agonist and examined their efficacy in cynomol
Autor:
In-Gyu Je, Seolhee Lee, Eunhye Jang, Jongmin Yoon, Kyungmi An, Yearin Jun, Don-Gil Lee, Haengjin Song, Hyun-Jung Kwak, Hyo-Jung Song, Dahae Hong, Jisu Kim, Jung Ho Kim, Chang-Hee Hong, Chorong Shin
Publikováno v:
Diabetes. 70
GPR40 has been considered a potential therapeutic target for type 2 diabetes because activation of GPR40 stimulates insulin secretion when glucose levels increased. Fasiglifam, a GPR40 agonist, was withdrawn from clinical development in Phase III due
Autor:
Chorong Shin, Yearin Jun, Hyun-Jung Kwak, Jongmin Yoon, Seolhee Lee, In-Gyu Je, Eunhye Jang, Haengjin Song, Jung Ho Kim, Chang-Hee Hong, Dahae Hong, Jisu Kim, Hyo-Jung Song, Kyungmi An, Don-Gil Lee
Publikováno v:
Diabetes. 70
GPR40/FFAR1 is a G-protein-coupled receptor predominantly expressed in pancreatic β-cells. GPR40 agonists are known to stimulate insulin secretion and reduce circulating glucose levels in a glucose-dependent manner. Currently, IDG-16177, as a GPR40